CompletedNCT00601536
Bioequivalency Study of 300 mg Lithium Carbonate Under Fasting Conditions
Medication studyAges 18–39United StatesBipolarity
Understand this study
Who was this study for?
Listed age limits: 18 years to 39 years.
- Listed locations
- PittsburghSee all locations and recruitment
Study information
Study start dateApril 2003
- Recruitment status
- Completed
- Enrollment listed in the registry
- 29
- Sponsor
- Roxane Laboratories
- Sponsor type
- Pharmaceutical company
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Not clearly listed
- Locations
- United States
- Age range
- From 18 Years to 39 Years
- Official registry ID
- NCT00601536
- Official title
Show the full official title
A Single Dose, Two-Period, Two-Treatment Crossover Bioequivalency Study of 300 mg Lithium Carbonate Extended Release Tablets Under Fasting Conditions.
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Pittsburgh
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Roxane Laboratories, a pharmaceutical company.
Did this study involve medication?
Yes. The study involved medication, including lithium.
Who was this study for?
Listed age limits: 18 years to 39 years.
